InventisBio | Evaluate

The search for a better Faslodex continues

Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.

October 06, 2020

Hints of moderation emerge in biotech venture funding

Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.

February 19, 2020

A blockbuster breast cancer niche has Roche and Sanofi in the lead

As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.